The pharmacology and mechanisms of action of atypical antipsychotic drugs: dopamine and beyond by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Annals of General Psychiatry
Open AccessOral presentation
The pharmacology and mechanisms of action of atypical 
antipsychotic drugs: dopamine and beyond
David Sanger*
Address: Sanofi-Aventis Research, Bagneux, France, European Editor, Behavioural Pharmacology
* Corresponding author    
The essential defining feature of atypical antipsychotic
drugs is that they are efficacious against the symptoms of
schizophrenia but produce fewer motor side effects (EPS)
than classical drugs. In addition, there is evidence that
atypical agents may be more effective than classical neu-
roleptics in treatment resistant patients and patients with
predominantly negative symptoms. All currently used
antipsychotics, both typical and atypical, have affinity for
the D2 family of dopamine receptors, at which they act as
antagonists. Nevertheless, because some atypical agents,
including clozapine, also bind to receptors for other neu-
rotransmitters, particularly serotonin, it has been pro-
posed that such additional mechanisms may be of
particular importance in producing an atypical pharmaco-
logical profile. However, there is evidence that selective
action at dopaminergic mechanisms in certain brain
regions can also give rise to antipsychotic efficacy with a
very low risk of EPS. Although most atypical drugs have
affinities for a variety of neurotransmitter receptors, two
drugs, amisulpride and aripiprazole, have been proposed
as selective dopaminergic agents. Amisulpride is a selec-
tive antagonist at dopamine D2 and D3 receptors whereas
aripiprazole may act through partial agonism at D2 recep-
tors. The good efficacy and safety of these drugs raise ques-
tions about the roles of neurotransmitters other than
dopamine. Nevertheless, a number of ongoing research
programmes are currently underway in the search for the
next generation of antipsychotics. While many of these
programmes target sites other than dopamine receptors
(including receptors for glutamate and neuropeptides), it
seems likely that indirect modulation of dopaminergic
neurotransmission will play a major role in their mecha-
nisms of action.
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